NCT04432233

Intravenous Triple Therapy in the Treatment of Helicobacter Pylori Infection and Related Complications Caused by Active Peptic Ulcer Disease

Intravenous Administration of Metronidazole, Levofloxacin and Esomeprazole Triple Therapy in the Treatment of Helicobacter Pylori Infection and Related Complications Caused by Active Peptic Ulcer Disease

• Status: Unknown
• Phase: Phase 4
• Study type: Interventional
• Enrollment: 60 (estimated)
• Sponsor: Shanghai Jiao Tong University School of Medicine · Academic / Other
• Sex: All
• Age: 18 Years – 75 Years
• Healthy volunteers: Not accepted

Summary

Helicobacter pylori infection causes active peptic ulcer disease and related complications like bleeding and pyloric obstruction. Usually, clinicians tended to treat Helicobacter pylori infection after active peptic ulcer disease and related complicaitons getting healed, which spent time and money. This study is designed to evaluate the efficacy and safety of intravenous administration of metronidazole, levofloxacin and esomeprazole triple therapy in the treatment of Helicobacter pylori infection combined with peptic ulcer disease related complications.

Conditions

• Helicobacter Pylori Infection
• Intravenous Drug Usage

Interventions

Type	Name	Description
DRUG	Esomeprazole	Proton pump inhibitor
DRUG	Metronidazole	antibiotic for H. pylori eradication
DRUG	Levofloxacin	antibiotic for H. pylori eradication

Timeline

• Start date: 2020-06-15
• Primary completion: 2021-04-15
• Completion: 2021-06-15
• First posted: 2020-06-16
• Last updated: 2020-08-27

Locations

1 site across 1 country: China